Celsense

 

 

NEWS RELEASE - For Immediate Release

Additional Patents for Cell Sense Issued by the USPTO

May 3, 2012 - Pittsburgh, Pennsylvania

Celsense, Inc. announced today that it has received additional notices of allowance for two US patent applications covering its magnetic resonance imaging (MRI) cell tracking product, Cell Sense. The additional patents include method claims for quantifying the number of transplanted cells in MRI images and compositions of matter.

The first patent covers methods for cell quantification. The allowed claims include methods for converting raw MRI data into a quantifiable biomarker for the number of transplanted cells in a user defined region of interest. The methods described in the patent are embodied in the company’s Voxel Tracker software product.

The second patent covers claims that include multiple formulations of Cell Sense now offered by the company, including the unique dual-mode (MRI and optical) reagent products.

Cell Sense is a family of perfluorocarbon tracer agents used to label cells ex vivo, making them detectable in vivo after transplantation using MRI. Cell Sense can be used to non-invasively image the administration, migration, and persistence of cells transplanted for therapeutic or diagnostic purposes.

Cell Sense is currently available for use in preclinical research and human clinical trials. The first clinical use of Cell Sense is in combination with an autologous dendritic cell vaccine used to treat colorectal cancer; the trial was authorized by the US FDA in May of 2011. It is contemplated that patient recruitment will commence in the summer of 2012.

The technology embodied in both patents was developed at Carnegie Mellon University and funded, in part, by multiple grants from the National Institutes of Health.  The two patents, “Cellular Labeling and Quantification for Nuclear Magnetic Resonance Techniques” and “Compositions and Methods for Producing Emulsions for Nuclear Magnetic Resonance Techniques” are assigned to Carnegie Mellon University and licensed to Celsense, Inc. on an exclusive basis. Ropes and Gray LLP acted as counsel to Carnegie Mellon University and Celsense, Inc., in the prosecution of the patent.

About Celsense, Inc.
Celsense, Inc. develops and markets novel products that enable the non-invasive imaging of populations of cells in vivo using MRI. Customers include leading pharmaceutical and biotechnology companies as well as biomedical research centers worldwide. Celsense’s mission is to be the standard for cellular imaging in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com